EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Fernanda Baeza Scagliusi iD, Bruno Gualano iD, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis

Obesity · 2026-09 · 34 (S2) · 9-12

DOI: 10.1002/oby.70069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 12.11.2025. Verfasst von Fernanda Baeza Scagliusi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Research Group in Eating, Corporalities and Culture (GPAC), University of São Paulo School of Public Health, São Paulo, São …. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Off-Label Use, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses around the off‐label use of GLP‐1ra to an individual goal of slimness rather than health. We propose that off‐label GLP‐1ra use by people with normative or mildly elevated weight reveals deeper tensions between scientific progress, stigma, and cultural ideals of the body. Understanding this phenomenon requires moving beyond biomedical efficacy to interrogate the psychological, behavioral, and sociopolitical implications of pharmacological thinness. Cross‐cultural and intersectional approaches from the social sciences are key to understanding this emergent phenomenon.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityOff-Label UseGlucagon-Like Peptide-1 Receptor AgonistsHumansSocial Stigma

Stichwörter der Autor:innen

anti‐obesity drugsobesityoff‐label useslimnesssociomedical aspects

Substanzen

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Nutrition, Research Group in Eating, Corporalities and Culture (GPAC), University of São Paulo School of Public Health, São Paulo, São Paulo, Brazil.
  • Department of Clinical Medicine, Center for Lifestyle Medicine (CMEV), University of São Paulo School of Medicine, São Paulo, São Paulo, Brazil.
  • The Danish National Center for Obesity, Aarhus University Hospital, Aarhus, Jutland, Denmark.
  • Arizona State University, School of Human Evolution and Social Change, Center for Global Health, Tempe, Arizona, USA.
  • Department of Public Health, Aarhus University, Aarhus, Jutland, Denmark.
  • Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Jutland, Denmark.

ORCID-Profile: Fernanda Baeza Scagliusi, Bruno Gualano

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Scagliusi, F. B., Gualano, B., Andreassen, P., SturtzSreetharan, C., Jensen, S. D., & Brewis, A. (2026). The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective. Obesity, 34(S2), 9-12. https://doi.org/10.1002/oby.70069

Vancouver

Scagliusi FB, Gualano B, Andreassen P, SturtzSreetharan C, Jensen SD, Brewis A. The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective. Obesity. 2026;34(S2):9-12. doi:10.1002/oby.70069

BibTeX
@article{Scagliusi2026,
  author = {Scagliusi, Fernanda Baeza and Gualano, Bruno and Andreassen, Pernille and SturtzSreetharan, Cindi and Jensen, Sissel Due and Brewis, Alexandra},
  title = {The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {S2},
  pages = {9--12},
  doi = {10.1002/oby.70069}
}
Kostenlos starten →